case_images: PMC10849748_01
case_images: Preoperative examinations. a Mammography showed a high-density mass with spiculation. b Ultrasonography revealed a hypoechoic nodular lesion of 2.2 x 2.0 x 1.7 cm. c Contrast-enhanced magnetic resonance imaging revealed a 21-mm round mass with central necrosis, exhibiting rim enhancement.
case_images: cro-2024-0017-0001-536212_F01.jpg
case_images: PMC10849748_01_cro-2024-0017-0001-536212_F01.jpg
case_images: F1
case_images: No distant organ and axillary lymph node metastases were detected on thoracic and abdominal computed tomography, classifying this patient as stage IIA T2N0M0 (Fig. 1).
case_images: Histological findings of invasive ductal carcinoma. a Hematoxylin and eosin staining showing invasive ductal carcinoma. Immunohistochemistry images showing expression of HER2 (b), ER (c), PR (d), AR (e), and Ki-67 (f). PR, progesterone receptor.
case_images: cro-2024-0017-0001-536212_F02.jpg
case_images: PMC10849748_01_cro-2024-0017-0001-536212_F02.jpg
case_images: F2
case_images: Histologic examination after core needle revealed histological grade 2, estrogen receptor (ER)/progesterone receptor-negative, human epidermal growth factor receptor 2 (HER-2)-positive, and invasive ductal carcinoma of the right breast (Fig. 2).
case_images: Overview of the clinical course.
case_images: cro-2024-0017-0001-536212_F03.jpg
case_images: PMC10849748_01_cro-2024-0017-0001-536212_F03.jpg
case_images: F3
case_images: Anastrozole and a gonadotropin-releasing hormone agonist were administered as adjuvant endocrine therapy. After 1 year, there was no recurrence, and laboratory workup revealed extremely low levels of estradiol and sex hormone levels consistent with male values: testosterone of 7.82 ng/mL (reference range for men: 1.31-8.71), estradiol less than 5.0 pg/mL (reference range for postmenopausal women and men: 0-47.0), LH of 0.1 mIU/mL (reference range for men: 0.79-5.72), and FSH of 6.28 mIU/mL (reference range for men: 2-8.3) (Fig. 3).